Breast and Cervical Cancer Early Detection and Control Advisory Committee, 2530 [E7-721]
Download as PDF
<![CDATA[
2530
Federal Register / Vol. 72, No. 12 / Friday, January 19, 2007 / Notices
and 7,500 ineligible screened persons
during a 3-year period. Data collection
will rotate such that interviews will be
conducted among one group per year:
MSM in year 1, IDU in year 2, and HET
in year 3. The type of data collected for
each group will vary slightly due to
different sampling methods and risk
characteristics of the group.
Participation of respondents is
voluntary and there is no cost to the
respondents other than their time.
ESTIMATED ANNUALIZED BURDEN HOURS
MSM:
Screener only ...........................................................................................
Screener, survey, and testing ..................................................................
IDU:
Screener only ...........................................................................................
Screener, survey, and testing ..................................................................
HET:
Screener only ...........................................................................................
Screener, survey, and testing ..................................................................
Total ...................................................................................................
Dated: January 12, 2007.
Deborah Holtzman,
Reports Clearance Officer, Centers for Disease
Control and Prevention.
[FR Doc. E7–705 Filed 1–18–07; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Breast and Cervical Cancer Early
Detection and Control Advisory
Committee
sroberts on PROD1PC70 with NOTICES
In accordance with section 10(a)(2)of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the aforementioned
committee meeting:
Times and Dates: 8:30 a.m.–5 p.m.,
February 6, 2007; 8:30 a.m.–3 p.m., February
7, 2007.
Place: Centers for Disease Control and
Prevention, 1600 Clifton Road, NE., Tom
Harkin Global Community Center, Building
19, Atlanta, Georgia 30333, Telephone: 404–
639–1717.
Status: Open to the public, limited only by
the space available.
Purpose: The committee is charged with
advising the Secretary, Department of Health
and Human Services, and the Director, CDC,
regarding the early detection and control of
breast and cervical cancer. The committee
makes recommendations regarding national
program goals and objectives;
implementation strategies; and program
priorities including surveillance,
epidemiologic investigations, education and
training, information dissemination,
professional interactions and collaborations,
and policy.
VerDate Aug<31>2005
18:10 Jan 18, 2007
Jkt 211001
Number of
responses per
respondent
Number of
respondents
Respondents
1
1
5/60
65/60
417
13,542
1,250
12,500
1
1
5/60
90/60
104
18,750
1,250
12,500
1
1
5/60
75/60
104
15,625
........................
........................
........................
48,542
Dated: January 12, 2007.
Edward Schultz,
Acting Director, Management Analysis and
Services Office, Center for Disease Control
and Prevention.
[FR Doc. E7–721 Filed 1–18–07; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Clinical Laboratory Improvement
Advisory Committee
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following committee
meeting.
Name: Clinical Laboratory Improvement
Advisory Committee (CLIAC). Web site:
Frm 00041
Fmt 4703
Total burden
(in hours)
5,000
12,500
Matters to be Discussed: The agenda will
include a review and discussion of the
National Breast and Cervical Cancer Early
Detection Program components; and
discussion and review of related policies and
emerging issues.
Agenda items are subject to change as
priorities dictate.
Contact Person for More Information:
Debra Younginer, Executive Secretary,
BCCEDCAC, Division of Cancer Prevention
and Control, National Center for Chronic
Disease Prevention and Health Promotion,
CDC, 4770 Buford Highway, Mailstop K–57,
Chamblee, Georgia 30316, Telephone: 770–
488–1074.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities for
both CDC and NCEH/ATSDR.
PO 00000
Average
burden per
response
(in hours)
Sfmt 4703
https://www.phppo.cdc.gov/CLIAC/
default.aspx.
Times and Dates: 8:30 a.m.–5 p.m.,
February 14, 2007; 8:30 a.m.–3 p.m.,
February 15, 2007.
Place: Omni Hotel at CNN Center, 100
CNN Center, Atlanta, Georgia 30303; Phone:
(404) 659–0000, Fax: (404) 525–5050 (https://
www.omnihotels.com/FindAHotel/
AtlantaCNNCenter.aspx).
Status: Open to the public, limited only by
the space available. The meeting room
accommodates approximately 100 people.
Purpose: This committee is charged with
providing scientific and technical advice and
guidance to the Secretary of Health and
Human Services, the Assistant Secretary for
Health, and the Director, CDC, regarding the
need for, and the nature of, revisions to the
standards under which clinical laboratories
are regulated, the impact on medical and
laboratory practice of proposed revisions to
the standards, and the modification of the
standards to accommodate technological
advances.
Matters to be Discussed: The agenda will
include updates from the CDC, the Centers
for Medicare & Medicaid Services, and the
Food and Drug Administration; discussion of
the status of the ‘‘Notice of Proposed
Rulemaking’’ for genetic testing;
presentations and discussion concerning the
future of health laboratory practice
specifically focusing on simple testing in
diverse sites; reports and discussions
addressing the impact of the Morbidity and
Mortality Weekly Report (MMWR)
Publication of ‘‘Good Laboratory Practices for
Waived Testing Sites’’; a report from the
CLIAC Workgroup on ‘‘The Impact of Rapid
and Molecular Tests for Infectious Disease
Agents on Public Health’’ and discussion of
the workgroup’s proposals related to such;
and presentations and discussion concerning
rapid HIV testing. Agenda items are subject
to change as priorities dictate.
Providing Oral or Written Comments: It is
the policy of CLIAC to accept written public
comments and provide a brief period for oral
public comments whenever possible.
E:\FR\FM\19JAN1.SGM
19JAN1
]]>Agencies
[Federal Register Volume 72, Number 12 (Friday, January 19, 2007)]
[Notices]
[Page 2530]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-721]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Breast and Cervical Cancer Early Detection and Control Advisory
Committee
In accordance with section 10(a)(2)of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces the aforementioned committee meeting:
Times and Dates: 8:30 a.m.-5 p.m., February 6, 2007; 8:30 a.m.-3
p.m., February 7, 2007.
Place: Centers for Disease Control and Prevention, 1600 Clifton
Road, NE., Tom Harkin Global Community Center, Building 19, Atlanta,
Georgia 30333, Telephone: 404-639-1717.
Status: Open to the public, limited only by the space available.
Purpose: The committee is charged with advising the Secretary,
Department of Health and Human Services, and the Director, CDC,
regarding the early detection and control of breast and cervical
cancer. The committee makes recommendations regarding national
program goals and objectives; implementation strategies; and program
priorities including surveillance, epidemiologic investigations,
education and training, information dissemination, professional
interactions and collaborations, and policy.
Matters to be Discussed: The agenda will include a review and
discussion of the National Breast and Cervical Cancer Early
Detection Program components; and discussion and review of related
policies and emerging issues.
Agenda items are subject to change as priorities dictate.
Contact Person for More Information: Debra Younginer, Executive
Secretary, BCCEDCAC, Division of Cancer Prevention and Control,
National Center for Chronic Disease Prevention and Health Promotion,
CDC, 4770 Buford Highway, Mailstop K-57, Chamblee, Georgia 30316,
Telephone: 770-488-1074.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining
to announcements of meetings and other committee management
activities for both CDC and NCEH/ATSDR.
Dated: January 12, 2007.
Edward Schultz,
Acting Director, Management Analysis and Services Office, Center for
Disease Control and Prevention.
[FR Doc. E7-721 Filed 1-18-07; 8:45 am]
BILLING CODE 4163-18-P
